xTool Debuts Silicon Valley HQ, Igniting a New Era of the Maker Movement in the U.S.

xTool's new Mountain View HQ and nationwide Fab Lab campaign put powerful tools in the hands of those shaping the future—creators, educators, and entrepreneurs alike

MOUNTAIN VIEW, Calif., July 31, 2025 /PRNewswire/ -- xTool, a global leader in desktop laser cutters and smart fabrication tools, today announced its official entry into the U.S. market with the grand opening of its Mountain View, Calif. headquarters. The move marks the start of what xTool calls the "New Era of the Maker Movement" or "Maker Movement 2.0": a new chapter where fabrication tools don't just live in garages, but in classrooms, labs, and startup studios across the country.

Click to Gallery

xTool Debuts Silicon Valley HQ, Igniting a New Era of the Maker Movement in the U.S.

xTool Debuts Silicon Valley HQ, Igniting a New Era of the Maker Movement in the U.S.

xTool Debuts Silicon Valley HQ, Igniting a New Era of the Maker Movement in the U.S.

xTool Debuts Silicon Valley HQ, Igniting a New Era of the Maker Movement in the U.S.

More Images

xTool Debuts Silicon Valley HQ, Igniting a New Era of the Maker Movement in the U.S.

xTool Debuts Silicon Valley HQ, Igniting a New Era of the Maker Movement in the U.S.

xTool Debuts Silicon Valley HQ, Igniting a New Era of the Maker Movement in the U.S.

xTool Debuts Silicon Valley HQ, Igniting a New Era of the Maker Movement in the U.S.

To celebrate the establishment of its first U.S. office in the epicenter of Silicon Valley's innovation, xTool will host a grand opening event at its office on Thursday, July 31, with the option to attend via livestream at 6:30pm PST. The event will feature live product demonstrations, facility tours, and a donation ceremony.

"xTool is redefining the maker economy in the U.S., not just with machines, but with a mission," said Jasen Wang, CEO of xTool. "This 'New Era of the Maker Movement' is about broadening access to advanced tools for a wider range of users at any skill level. By establishing roots in Silicon Valley and supporting Fab Labs across the U.S., we're investing in a new generation of creators—those who will turn ideas into action and side projects into scalable businesses."

As part of this mission, xTool recently launched its F2 Ultra, a powerful, dual-laser engraver combining 60W MOPA fiber and 40W diode technology. Compact yet industrial-grade, the F2U is engineered to empower creators with high-speed, high-precision performance across materials, enabling makers to turn ideas into real products, businesses, and impact.

Strategic U.S. Expansion

xTool's Mountain View headquarters marks a major step in its U.S. expansion, supporting the growth of its demo rooms, customer service operations, and the "xTool Squad" program — a new localized support network. By the end of the year, xTool aims to bring on board up to 700 independent partners across the country to join the xTool Squad and provide hands-on assistance to customers in their communities.

With over 500,000 users and counting, xTool's U.S. growth strategy includes:

• Supporting local entrepreneurs and small businesses
• Establishing retail and educational-focused partnerships
• Expanding local service to provide industry-leading support for its community

"I'm excited to see xTool's innovative tools reaching more educators and makers," said Dale Dougherty, founder of MAKE: Magazine. "With the right tools and a creative mindset, anyone can become a maker. xTool is helping more people bring their ideas to life and inspiring the next generation of inventors."

Empowering the Next Generation of Makers

As part of its mission to make advanced fabrication technology more accessible, xTool is donating 50 laser machines—valued at over $200,000—to schools, makerspaces, and educational organizations across the U.S. in 2025.

Early recipients include local community hubs like Maker Nexus, purpose-driven organizations such as Black Horse Forge, which supports veterans and first responders, and renowned institutions like MIT and Stanford.

xTool is also expanding its partnership with the Fab Foundation's global Fab Lab network, including a cornerstone donation to the new Fab Lab HQ in Boston, and powering the Fab-In-A-Box initiative—an affordable, accessible and engaging mobile fabrication program.

"The Fab Foundation was founded on the idea that anyone, anywhere, can make almost anything if they have access to the right tools and knowledge," said Sherry Lassiter, President and Co-Founder of the Fab Foundation. "Together with our partners and the global Fab Lab network, we're unlocking creativity, expanding opportunity, and building a more inclusive and sustainable future for all."

xTool is calling on Fab Labs, makerspaces, schools and educational programs across the U.S. to join its mission to spark creativity and expand access to digital fabrication. If your organization is interested in partnering with xTool to empower the next generation of creators and explore opportunities for laser machine donations, please apply here.

About xTool:

xTool is a global leader in desktop laser cutters, engravers, and smart fabrication tools. Since 2020, xTool has empowered creators in over 62 countries, supported by 322 patents and 12 world-first innovations. xTool is transforming how people learn, create, and build—from classrooms to research labs, from garages to retail stores. Combining powerful technology with intuitive design, xTool makes advanced fabrication tools accessible to makers, educators, and entrepreneurs everywhere. Learn more at xTool.com.

Media Contact:
xTool Public Relations
pr@xtool.com 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

xTool Debuts Silicon Valley HQ, Igniting a New Era of the Maker Movement in the U.S.

xTool Debuts Silicon Valley HQ, Igniting a New Era of the Maker Movement in the U.S.

xTool Debuts Silicon Valley HQ, Igniting a New Era of the Maker Movement in the U.S.

xTool Debuts Silicon Valley HQ, Igniting a New Era of the Maker Movement in the U.S.

HIGHLIGHTS

• Following an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review Committee (SRC) confirms the trial will continue with no modifications to the protocol.

Patient population

• With the SECuRE trial continuing to recruit, a total of nine participants who had evaluable data by the 25^th of November 2025 were included in the interim assessment by the SRC, with the majority of participants receiving at least two cycles of 8 GBq of ⁶⁷Cu-SAR-bisPSMA each by the data cut-off date.
• Seven participants received ⁶⁷Cu-SAR-bisPSMA and two participants were treated with a combination of ⁶⁷Cu-SAR-bisPSMA with enzalutamide.
• Most participants were heavily pre-treated (with 55.6% having received more than 5 previous anti-cancer regimens) and had bone metastasis (66.7%).

Safety

• The safety profile of ⁶⁷Cu-SAR-bisPSMA remains favourable with most related adverse events (AEs) in the Cohort Expansion to date being Grade 1 or 2. The most common AEs were nausea and lymphopenia (observed in 33.3% of participants, for each AE).

Efficacy

• Six participants had at least two prostate specific antigen (PSA) results following ⁶⁷Cu-SAR-bisPSMA administration, with all showing a decrease in PSA. Of those, four participants (66.7%) thus far had a reduction of more than 50% in PSA (PSA50) and two participants (33.3%) had a reduction of more than 80% (PSA80).
• One participant who presented with bone metastasis at enrolment achieved undetectable PSA with no prostate cancer detected by computed tomography (CT) or bone scan following ⁶⁷Cu-SAR-bisPSMA treatment. The participant reported having excellent quality of life following the treatment.

Next Steps

• The SECuRE trial will continue enrolment into the Cohort Expansion Phase with planned completion of recruitment in 2026. Phase III registrational trial planning ongoing based on data generated to date.

SYDNEY, Jan. 15, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to share a number of updates on the SECuRE trial following an SRC meeting. The SRC has recommended that the trial continue with the Cohort Expansion Phase (Phase II) as planned with no modifications to the protocol. The interim results assessed by the SRC were collected from nine participants enrolled in the cohort that had evaluable data by the cut-off date of the 25^th of November 2025 and continue to show promising efficacy and a favourable safety profile of ⁶⁷Cu-SAR-bisPSMA.

The majority of the nine participants had bone metastasis at enrolment (66.7%) and received multiple lines of previous treatments (more than 5 previous anti-cancer regimens, 55.6%). Median PSA prior to ⁶⁷Cu-SAR-bisPSMA treatment was 18.9 ng/mL (range 1.5-30.2 ng/mL). Six out of these nine participants received at least 2 cycles of 8 GBq of ⁶⁷Cu-SAR-bisPSMA each, with two of them also receiving concomitant enzalutamide.

Of the nine participants included in this SRC analysis, six had at least two PSA results following their ⁶⁷Cu-SAR-bisPSMA treatment by the data cut-off date. Of these six participants, thus far four (66.7%) showed reductions in PSA of 50% or more (PSA50) and two (33.3%) showed reductions of 80% or more (PSA80).

The safety profile of ⁶⁷Cu-SAR-bisPSMA remains favourable in the Cohort Expansion, with the majority of related AEs being Grade 1 or 2. The most common related AEs were nausea and lymphopenia (observed in three out of nine participants [33.3%], for each AE). The only AE that was Grade 3 or above was lymphopenia observed in three participants, some of whom had bone metastasis at baseline and/or had received multiple lines of therapy, including taxane and an investigational agent, prior to enrolment in the SECuRE study. There have been no overall renal toxicity or electrocardiogram (ECG) changes observed in these participants. In the combination enzalutamide arm, no new AEs (or worsening of AEs) related to ⁶⁷Cu-SAR-bisPSMA have been observed to date.

Trial participant with no detectable disease after 3 cycles of ⁶⁷Cu-SAR-bisPSMA

One of the participants in the Cohort Expansion was a 64-year-old man with bone metastases and baseline PSA of 5.4 ng/mL prior to entering the SECuRE study. Following his first cycle of ⁶⁷Cu-SAR-bisPSMA, this participant showed a dramatic 95.2% reduction in PSA. He went on to receive 2 more cycles of ⁶⁷Cu-SAR-bisPSMA and achieved undetectable PSA levels. In a follow-up bone scan and CT no metastatic disease was observed. This participant only exhibited mild (Grade 1) related AEs, most of which were gastrointestinal events, with no haematological or renal AEs observed. The participant reported having excellent quality of life following the treatment.

The interim data from this Phase II continues to confirm the favourable safety profile and promising efficacy seen in previous cohorts of the SECuRE trial^[1] and supports the continuation of the trial with the aim to progress to a registrational Phase III study.

Clarity's Executive Chairperson, Dr Alan Taylor, commented, "SAR-bisPSMA continues generating world-class data in both theranostic and diagnostic trials. The combination of the optimised dimer 'bis' structure with the benefits of copper isotopes, enabled by the proprietary sarcophagine technology, is proving to have created a product that is here to challenge the current treatment and diagnostic paradigms in radiopharmaceuticals.

"We have already seen a glimpse of the effects of ⁶⁷Cu-SAR-bisPSMA through our Dose Escalation cohorts with additional and similar data being generated in the Cohort Expansion phase, demonstrating once again excellent efficacy and safety results of ⁶⁷Cu-SAR-bisPSMA.

"All of the participants with evaluable data treated in the Phase II to date have shown declines in PSA, with the majority showing PSA decreases of more than 50% and mostly having only mild or moderate AEs. Most of these patients have been treated with more than 5 systemic treatment regiments and had bone metastasis prior to entering the SECuRE study. Although the number of participants with evaluable data to date is small, it is incredible to see yet another extraordinary case where a patient who had bone metastasis prior to entering the study achieved undetectable PSA following ⁶⁷Cu-SAR-bisPSMA treatment, with no disease observed by anatomical and molecular imaging at the last assessments. This participant only experienced mild, transient AEs, most being gastrointestinal, and has reported having excellent quality of life following the treatment.

"Importantly, the work we have undertaken during the Dose Escalation Phase is now continuing to provide a strong foundation for us as we look ahead at protocol development and dosing for our Phase III clinical trial and commercialisation. As the participant numbers continue to increase with the trial enrollment, we continue to see very promising responses over and over again, giving us more confidence about the future of this product and its potential for commercialisation in metastatic castration-resistant prostate cancer (mCRPC). With three Fast Track Designations for the SAR-bisPSMA product and positive interactions with the US Food and Drug Administration (FDA) to date, we are working towards bringing this agent to clinicians and their patients around the world through the entirety of the prostate cancer journey, from first diagnosis to late-stage disease. All of these indications, being imaging in pre-definitive therapy and biochemical recurrence, as well as therapy in mCRPC, are blockbuster markets individually for prostate-specific membrane antigen (PSMA) targeted products, with an estimated combined market value of approximately US$10-15 billion by 2030. We are committed to continuing the development of this product, aiming to bring improved diagnostic and treatment options for prostate cancer in various stages of their disease."

About the SECuRE trial

The SECuRE trial (NCT04868604)^[2] is a Phase I/IIa theranostic trial for identification and treatment of participants with PSMA-expressing mCRPC using ⁶⁴Cu/⁶⁷Cu-SAR-bisPSMA. ⁶⁴Cu-SAR-bisPSMA is used to visualise PSMA-expressing lesions and select candidates for subsequent ⁶⁷Cu-SAR-bisPSMA therapy. The trial is a multi-centre, single arm, dose escalation study with a cohort expansion involving approximately 54 participants in the US. The overall aim of the trial is to determine the safety and efficacy of ⁶⁷Cu-SAR-bisPSMA for the treatment of prostate cancer.

The SECuRE trial consists of the Dose Escalation (Phase I) and Cohort Expansion (Phase II) Phases. Based on the data from the Dose Escalation Phase, which demonstrated a favourable safety profile and efficacy of ⁶⁷Cu-SAR-bisPSMA, the SECuRE trial progressed to the Cohort Expansion (Phase II) at an 8 GBq dose level as per the SRC recommendation (up to 6 cycles per patient in total)^[3].

Cohort 2 of the Dose Escalation phase of the trial, where participants were dosed with 8 GBq of ⁶⁷Cu-SAR-bisPSMA, demonstrated a very low rate of related AEs while all three participants achieved PSA declines of 80% or more (PSA80)^[1]. The Dose Escalation Phase also showed high PSA response rates of the mCRPC in the pre-chemotherapy setting with a favourable safety profile: 92% of pre-chemotherapy participants (12/13) demonstrated PSA drops greater than 35%, PSA reductions greater than 50% were reached in 61.5% (8/13) of participants, and reductions of 80% or more were achieved in 46.2% (6/13) of participants^[1]. These results supported the progress of the trial to its Cohort Expansion Phase using 8 GBq multi-dose in participants who had not received chemotherapy in the mCRPC setting.

Recruitment is currently ongoing into the Cohort Expansion Phase which will include 24 participants. A subset of participants will be treated with the combination of 8 GBq of ⁶⁷Cu-SAR-bisPSMA with enzalutamide (androgen receptor pathway inhibitor [ARPI]), in line with the positive results from the Enza-p trial^[4] and previous discussions with and advice from key global medical experts in the field of prostate cancer, including the Company's Clinical Advisory Board members, Prof Louise Emmett and Prof Oliver Sartor, as well as the SRC.

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word "bis", which reflects a novel approach of connecting two PSMA-targeting agents to Clarity's proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or ⁶⁴Cu) for imaging and copper-67 (Cu-67 or ⁶⁷Cu) for therapy.

⁶⁷Cu-SAR-bisPSMA and ⁶⁴Cu-SAR-bisPSMA are unregistered products. The safety and efficacy of ⁶⁷Cu-SAR-bisPSMA and ⁶⁴Cu-SAR-bisPSMA have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that these products will become commercially available.

About Prostate Cancer

Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide^[5]. Prostate cancer is the second-leading causes of cancer death in American men. The American Cancer Institute estimates in 2025 there will be about 313,780 new cases of prostate cancer in the US and around 35,770 deaths from the disease^[6].

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing TCTs based on its SAR Technology Platform for the treatment of cancers.

www.claritypharmaceuticals.com

For more information, please contact: